AFP Forum

AFP launches its new multimedia platform, AFP Forum: the entire news production in text, photo, video and infographics available on one site and in 6 languages.

AFP selected to help develop fact-checking in Hungary

Agence France-Presse, a global leader in digital investigation, has been selected in an open tender by the European Commission to help in the fight against disinformation in Hungary, which to date has no other recognised organisation in this field.

Agence France-Presse, a global leader in digital investigation, has been selected in an open tender by the European Commission to help in the fight against disinformation in Hungary, which to date has no other recognised organisation in this field.
Anglais

AFP and Google sign an agreement on neighbouring rights

Agence France-Presse and Google today announced an agreement on the remuneration of neighbouring rights under French law. This follows months of constructive negotiations within the framework set by the French Competition Authority. The wider partnership with AFP will also encompass other projects, including a program dedicated to fact checking, with more details to be shared soon.

Agence France-Presse and Google today announced an agreement on the remuneration of neighbouring rights under French law. This follows months of constructive negotiations within the framework set by the French Competition Authority. The wider partnership with AFP will also encompass other projects, including a program dedicated to fact checking, with more details to be shared soon.
Anglais
03/11/2026 06:00
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan

Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition f...

03/11/2026 06:00
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence

As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of for...

03/11/2026 06:00
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurch...